1 of 1
Story summary
- Pfizer Inc. signals a strategic shift away from pandemic-focused revenue, prioritizing margin protection and growth.
- The company has raised prices on about 80 drugs, including Ibrance and Nurtec, to bolster profitability.
- Pfizer's 2026 revenue forecast is between $59.5 and $62.5 billion, reflecting potential $1.5 billion decline from exclusivity losses.
- Key milestones include clinical data on the Metsera pipeline and the impact of price increases on revenue stabilization.
